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Abstract
Several studies have suggested an association between use of metformin and an increased overall survival in patients diagnosed with
pancreatic cancer, however with several important methodological limitations. The aim of the study was to assess the association
between overall survival, pancreatic cancer, and metformin use.
A retrospective cohort study of 1111 patients with pancreatic cancer was conducted using data from The Netherlands
Comprehensive Cancer Organization (1998–2011). Data were linked to the PHARMO Database Network containing drug-
dispensing records from community pharmacies. Patients were classified as metformin user or sulfonylurea derivatives user from the
moment of first dispensing until the end of follow up. The difference in overall survival between metformin users and nonusers was
assessed, and additionally between metformin users and sulfonylurea derivatives users. Univariable and multivariable parametric
survival models were used and use of metformin and sulfonylurea derivatives was included as time-varying covariates.
Of the 1111 patients, 91 patients were excluded because of differences in morphology, 48 patients because of using merely
metformin before diagnosis, and 57 metformin-users ever used contemporary sulfonylurea derivatives and were therefore excluded.
Lastly, 8 patients with a survival of zero months were excluded. This resulted in 907 patients for the analysis. Overall, 77 users of
metformin, 43 users of sulfonylurea derivatives, and 787 nonusers were identified. The adjusted rate ratio for overall survival for
metformin users versus nonusers was 0.86 (95%CI: 0.66–1.11; P=0.25). The difference in overall survival between metformin users
and sulfonylurea derivatives users showed an adjusted rate ratio of 0.90 (95% CI: 0.59–1.40; P=0.67).
No association was found between overall survival, pancreatic cancer, andmetformin use. This was in concordance with 2 recently
published randomized controlled trials. Future research should focus on the use of adjuvant metformin in other cancer types and the
development or repurposing of other drugs for pancreatic cancer.
Abbreviations: ATC = anatomical therapeutic chemical, ECR = Eindhoven Cancer Registry, IQR = interquartile range, OGLD =
oral glucose-lowering drug, RR = rate ratio, SD = sulfonylurea derivatives.
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1. Introduction
Pancreatic cancer is the eighth most common cause of cancer
deaths in the world.[1] Only 10%–20% of patients with
pancreatic cancer qualify for surgery and the prognosis of this
disease is poor; median survival for patients undergoing surgery
ranges from 20 to 23 months.[2,3] For patients receiving solely
chemotherapy, survival approximately ranges from 3 to 11
months.[1,4] With this limited prognosis, there is a high and
urgent need for new therapies to improve outcome.
Smoking, obesity, and type 2 diabetes are considered to be
important risk factors for the development of pancreatic
cancer.[5,6] Metformin is the first-line treatment for patients
with type 2 diabetes and is therefore the most prescribed oral
glucose-lowering drug (OGLD). The decision to prescribe
metformin depends on patient characteristics; metformin use is
contraindicated in patients with renal failure, cardiac dysfunc-
tion, and hepatic insufficiency.[7] Metformin is a biguanide
antihyperglycemic agent and has 3 working mechanisms: it
decreases the hepatic glucose production by inhibition of
gluconeogenesis and glycogenolysis in muscles, it subsequently
improves peripheral insulin sensitivity, and reduces glucose
absorption.[7–9] Mouse models suggest that metformin could
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inhibit the proliferation of xenografted human pancreatic cancer
cells within 30 days, but other studies point toward a systemic
effect of metformin on cancer by improving the metabolic profile
of patients, rather than a direct effect on tumor cells.[9–12]
Recent epidemiologic cohort studies in patients with type 2
diabetes have suggested that patients using metformin have a
decreased risk of developing cancer and, possibly, a reduced
cancer mortality.[13–16]
Several meta-analysis pointed out that the reduced cancer
incidence was not present in all types of cancer; use of metformin
seems to be associated with a reduced risk of developing cancer in
patients with pancreatic, colorectal, and hepatocellular cancer,
with conflicting results for breast cancer, and no association is
seen in patients with lung and prostate cancers.[17–21] Preceding
epidemiologic studies assessing the effect of metformin on the risk
of cancer and survival may have been subject to several time-
related biases, for example, misclassifying exposure to metfor-
min, which could have inflated the estimates. Three studies
avoiding these biases have found no effect ofmetformin on cancer
incidence.[22] What additionally complicates observational
studies on this subject, is that patients using metformin often
have other comorbidities supplementary to type 2 diabetes,
compared with nonusers. Alternative treatment for type 2
diabetes are sulfonylurea derivatives (SD) which have been used
previously as a comparator group in addition to nonusers.[15]
The aim of this study was to assess the association between the
use of metformin and overall survival in patients with pancreatic
cancer with the use of appropriate methodology, a pitfall of the
previous studies. Patients using metformin were compared with
nonusers and additionally to patients using SD.
2. Methods
2.1. Data
Data from the Eindhoven Cancer Registry (ECR) were linked on
patient level to the PHARMO Database Network covering a
demographic region in the South-Eastern part of The
Netherlands of ∼1.5 million inhabitants.[23] The ECR is
maintained by The Netherlands Comprehensive Cancer Organi-
sation and registers newly diagnosed cancer patients from 10
different hospitals located in this region. Patients are informed
about this registration and are registered except patients who
objected to be registered. The Netherlands Cancer Registry is
obliged to work according to the law about protection of privacy
data and all procedures to privacy of doctors and patients is fixed
in regulations. An independent Committee of Privacy reassures
that The Netherlands Cancer Registry is compliant to these
regulations. Therefore, informed consent of the patients for this
specific study was not applicable.
The PHARMO Database Network is a population-based
network of healthcare databases and combines data from different
healthcare settings in The Netherlands. For this study, the
Outpatient PharmacyDatabase is used containing drug-dispensing
records from community pharmacies. All dispensed drugs are
coded according to the Anatomical Therapeutic Chemical (ATC)
classification (www.whocc.no/atc_ddd_index), and the records
include informationon typeofproduct, date, dosage, andquantity.
2.2. Study population
All patients diagnosedwith amalignancyof thepancreas (classified
according to the International Statistical Classification of Diseases
and Related Health Problems – 10th revision code C-25) between
1998 and 2011were selected from theECR-PHARMOcohort. To
reduce confounding by indication, metformin users were, in
addition to nonusers, compared with SD users. Excluded were
malignancies with the following morphology: squamous cell
carcinoma, epithelial carcinoma, cystic/mucinous/serous carcino-
ma, or gastrointestinal stromal tumor because of the differences in
disease course. The in- and excluded morphology codes can be
found in supplementary Table 1.
2.3. Exposure
Patients using metformin (ATC-code: A10BA02) or SD (ATC-
code: A10BB) for at least 30 days were defined as users. Users
were defined as patients using metformin before and after
diagnosis, or only after diagnosis, and not using contemporary
SD users. Patients who used metformin solely before diagnosis
were excluded from this analysis. Nonusers were defined as
patients who never used metformin or SD. SD users were defined
as patients who used solely SD.
2.4. Analysis
The period of metformin or SD use was defined from the first
dispensing of metformin or SD to the end of the follow-up period.
Follow-up time was determined from date of diagnosis (T0) until
death or end of the study period at 31 December 2012. Cancer
registry data were linked to municipal population registries to
obtain vital status. To determine time-dependent exposure,
patients were defined as nonusers from T0 to the date of first
metformin or SD use. Differences in patient characteristics
between metformin users and nonusers and between metformin
users and SD users were analyzed using the independent samples
t-test and the chi square test.
A Kaplan–Meier survival curve was constructed to compare
overall survival between patients using metformin, SD, and
nonusers. A parametric survival model with exponential
(Poisson) distribution was used to model the effect of metformin
use on overall survival, where death of any cause was coded as
event. Metformin use and SD use were included as time-varying
covariates in the model.
Overall survival between metformin users and nonusers was
assessed.Adjustmentsweremade for age, number of comorbidities
(0, 1, or≥2, excluding diabetesmellitus), Tumor-Node-Metastasis
(TNM) stage (categorical), year of diagnosis (1998–2003,
2004–2007, and 2008–2011), surgery (yes/no), chemotherapy
(yes/no), and radiotherapy (yes/no). Information about comorbid-
ities was available for lung disease, cardiovascular disease,
diabetes, disorders of the gastrointestinal tract, urinary tract,
nervous system, musculoskeletal system, and a group of other
comorbidities. Unknown values were taken into account as
categorical variables in the multivariable model. The difference
between overall survival in metformin users and SD users was
analyzed with the same model that was used for the analysis of
metformin versus nonusers. The results of the model should be
interpreted as a favorable associationwith survival when the result
shows a rate ratio <1 in relation to the comparison group.
All analyses were performed using Stata version 12 statistical
software. Statistical tests were 2-sided and considered significant
at the P<0.05 level.
3. Results
In total, 1111 patients with pancreatic cancer were diagnosed in
the period 1998–2011; 91 patients were excluded because of
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morphology (as described above) and 48 patients were excluded
because of using merely metformin before diagnosis (Fig. 1,
flow chart of the study population). Overall, 57 metformin users
ever used contemporary SD and were therefore excluded. Eight
patients with a survival of zero months were excluded from the
analysis. This resulted in a study population of 907 patients, of
which 77 patients used metformin and 43 used SD as drug for
diabetes type 2.
In total, 863 events were reported. In the metformin group,
64 patients deceased during study period, and in the SD group 41
patients deceased.
Table 1 shows the characteristics of this population. There
were no significant differences between the groups concerning
TNM stage and treatment (chemotherapy, radiotherapy, and
surgery). Metformin users had more additional comorbidities
(P<0.001) compared with both nonusers and SD users.
Incidence of diabetes did not differ between the group of
metformin users and SD users. Contemporary insulin use was
36% for metformin users versus 33% among patients using SD
(P=0.70). Patients who used metformin were diagnosed in more
recent years than SD users or nonusers (P<0.001). Finally,
median survival of metformin users was 5.7 months (interquartile
range [IQR]: 2.2–14.7), SD users had a median survival of 6.0
(IQR: 1.6–21.2) months, whereas nonusers had a median
survival of 4.0 months (IQR: 1.5–9.2).
Table 2 shows the analysis of overall survival difference
between metformin users and nonusers. For all patients with
pancreatic cancer, metformin use was associated with an
improved overall survival compared with patients not using
metformin, rate ratio (RR) 0.76 (95% CI: 0.59–0.98; P=0.04;
Table 2). This association was no longer significant after
adjusting for age, number of comorbidities, stage, year of
diagnosis, surgery, chemotherapy, and radiotherapy. Multivari-
able RR for metformin users compared with nonusers was 0.86
(95% CI: 0.66–1.12; P=0.26).
Overall survival was additionally assessed between the
following 3 groups: patients not using OGLD, metformin users,
and SD users (Fig. 2, Table 2). Overall survival for metformin
users versus nonusers was RR 0.74 (95% CI: 0.57–0.95; P=
0.02). After adjusting for potential confounders, the RR for
overall survival of metformin users versus nonusers was 0.85
(95% CI: 0.65–1.11; P=0.23). Overall survival for SD users
compared with nonusers was RR = 0.60 (95% CI: 0.44–0.82;
P=0.001), and multivariable analysis showed an RR = 0.82
(95% CI: 0.59–1.13; P=0.23).
Lastly, Table 2 shows the comparison of metformin users
versus SD users. SD use was not associated with overall survival
compared with metformin users. RR was 0.78 (95% CI:
0.53–1.15; P=0.21) and adjusted RR was 0.86 (95% CI:
0.50–1.46; P=0.57).
4. Discussion
This retrospective, observational cohort study showed no
association between the use of metformin and overall survival
in patients with pancreatic cancer.
Table 1
Characteristics of the cohort.
Overall Nonuser
∗
Metformin users Metformin users Sulfonylurea derivative users
n % n % n % P value† n % n % P-value‡
Total 907 830 77 77 43
Sex
Male 486 54 442 53 44 57 0.552 44 57 30 70 0.18
Female 421 46 388 47 33 43 33 43 13 30
Age at diagnosis, y (mean, SD) 69 (±11) 69 (±11) 70 (±10) 0.322 70 (±10) 71 (±10)
Year of diagnosis
1998–2003 242 27 238 29 4 5 <0.001 4 5 25 58 <0.001
2004–2007 287 32 262 31 25 33 25 33 12 28
2008–2011 377 41 329 40 48 62 48 62 6 14
Number of comorbidities
0 226 25 226 27 0 0 <0.001 0 0 6 14 0.003
1 245 27 225 27 20 26 20 26 15 35
≥2 321 35 274 33 47 61 47 61 18 42
Unknown 115 13 105 13 10 13 10 13 4 9
Diabetes yes 155 17 103 12 52 68 <0.001 52 68 24 56 0.17
TNM stage
1 36 4 31 4 5 7 0.733 5 7 1 2 0.56
2 90 10 81 10 9 12 9 12 4 9
3 62 7 59 7 3 4 3 4 3 7
4 312 34 286 34 26 34 26 34 11 26
Unknown 407 45 373 45 34 44 34 44 24 56
Treatment
Surgery (yes) 98 11 86 10 12 16 0.177 12 16 5 12 0.79
Radiotherapy (yes) 38 4 33 4 5 7 0.364 5 7 4 9 0.72
Chemotherapy (yes) 210 23 190 23 20 26 0.572 20 26 8 19 0.50
Insulin use ever 115 13 87 11 28 36 <0.001 28 36 14 33 0.70
Significant differences are printed in bold.
TNM = tumor-node-metastasis, SD = standard deviation.
∗
Nonusers include sulfonylurea derivatives user.
† P-value for nonusers versus metformin users.
‡ P-value for metformin versus sulfonylurea derivatives users.
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These results are in concordance with the results of 2
retrospective cohort studies. These studies found no association
between the use of metformin and survival in patients with
(advanced) pancreatic cancer; however, these studies were only
done in respectively 44 and 516 patients with type 2 diabetes
mellitus.[24,25] Similarly, 2 recently published randomized
controlled trials – carried out in 121 patients in the Netherlands
and 60 patients in Italy – also showed no effect of metformin on
survival.[26,27] Despite differences in design, such as cancer stage,
chemotherapy regime, blinding, and use of placebo, both trials
show a consistent no effect of metformin on survival in patients
with advanced pancreatic cancer.
The results of the randomized controlled trials and our study
are in conflict with numerous other observational studies
describing a beneficial effect of metformin, not only in pancreatic
cancer.[15,19,28–32]Mortality decrease for patients with pancreatic
cancer using metformin was consistently 27%–40% in previous
studies; however, these cohorts were smaller than the cohort that
was analyzed in this study, with respectively 302, 764, and 349
patients who were analyzed.[28–30] This discrepancy could be
Figure 1. Flowchart of patients selected for analysis.
Table 2
Time-dependent survival analysis.
n Rate ratio (95% CI) P-value Adjusted rate ratio
∗
(95% CI) P-value
Metformin users versus nonusers
Nonusers† 830 1 (Reference) 1 (Reference)
Metformin users 77 0.76 (0.59–0.98) 0.04 0.86 (0.66–1.12) 0.26
Nonusers versus metformin users and sulfonylurea derivatives users
Nonusers‡ 787 1 (Reference) 1 (Reference)
Metformin users 77 0.74 (0.57–0.95) 0.02 0.85 (0.65–1.11) 0.23
Sulfonylurea derivatives users 43 0.60 (0.44–0.82) 0.001 0.82 (0.59–1.13) 0.23
Metformin users versus sulfonylurea derivatives users
Metformin users 77 1 (Reference) 1 (Reference)
Sulfonylurea derivatives users 43 0.78 (0.53–1.15) 0.21 0.86 (0.50–1.46) 0.57
Significant differences are printed in bold.
CI = confidence interval.
∗
Adjusted for age, number of comorbidities, stage, year of diagnosis, and therapy (surgery, radiotherapy, and chemotherapy).
† Nonusers including sulfonylurea derivatives users.
‡ Nonusers do not include sulfonylurea derivatives users.
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partly explained by the difference in methodology.[8] Suissa and
Azoulay[22] studied the effect of time-related biases in observa-
tional drug studies of metformin on cancer. Authors state that
using time-varying techniques prevents misclassification of
metformin exposure. There have been several publications
claiming to account for these biases. These studies could not
demonstrate any association between metformin and cancer
incidence or the observed incidence reduction was considerably
smaller than previous results.[22,33,34] Another explanation could
be the high number of patients with irresectable pancreatic cancer
(89%) in our study, whereas other studies found a survival
benefit in patients with resectable pancreatic cancer.[29,32]
In addition, differences in patient characteristics could partly
explain the results of our study. Patients using SD had less
comorbidities than metformin users. Before 2006, the guidelines
recommended prescription of metformin for patients with a body
mass index (BMI) >27.[35,36] It could therefore be possible that a
majority of the patients who were prescribed metformin (35%)
before 2006 were overweight. Obese patients have a worse
prognosis and overall survival, partly because of a higher risk
surgical risk.[37] This observation could also partly explain the
observed trend toward a better survival for patients using SD,
however no information on BMI was available in the present
dataset.
For the direct action of metformin on cancer cells, the effective
drug concentrations achieved in neoplastic tissue are crucial.[38] It
is possible that the required concentration in the target tissue is
not attained with the present dose of metformin. Because of the
retrospective nature of this study, no information is available
about sufficient concentrations of the effect on tumor cells.[38]
The Dutch randomized controlled trial has also addressed this
aspect, where an effect on survival was found in a subset of
patients reaching adequate insulin level decrease.[26]
Our study has some notable strengths. First, this is one of the
largest cohorts so far to analyze the association between the use
of metformin and survival in patients with pancreatic cancer.
Second, our data are linked through 2 validated databases—ECR
and PHARMO—preventing both recall and information bias.
Third, this is the first observational study adressing the
association between the use of metformin and overall survival
in patients with pancreatic cancer, taking into account the time
between the beginning of the follow up and the first drug
prescription, which prevents time-related biases. Not including
the time-varying covariate in our model also revealed a highly
significant survival benefit for metformin users. Additionally,
metformin users were compared with SD users, a group of
patients with a more similar baseline prognosis. Lastly, previous
articles focused on the effect of metformin on overall survival
limited to patients with pancreatic cancer and type 2 diabetes,
whereas this study included all patients with pancreatic cancer.
A limitation to this observational study could be the small
number of patients who received OGLD in a large cohort, which
also complicated a subgroup analysis, for example, in patients
who underwent a resection. Only 43 patients were solely using
SD, and because of this small number of users, no robust
statements can be made. However, because of the wide interest in
a growing field, this remains a relevant study, complementing the
existing evidence. Moreover, because of the retrospective nature
of the study, the amount of information available is limited.
There is no detailed information about the population such as
smoking, BMI, glycemic control, or cause of death. It could
hypothetically be possible that the nonsignificant relative risk
reduction of 15% found in the adjusted analysis was not
significant due to a lack of power. However, in the randomized
controlled trials recently published, no effect of metformin on
survival of patients with pancreatic cancer could be proven, and
these trials were of course designed with a power calculation.
This observational study contributes to the mounting evidence
against an association between improved survival in patients with
pancreatic cancer using metformin.[24,26,27,39] These findings
could discourage new trials to be designed for metformin as
adjuvant therapy in pancreatic cancer, as this disease is generally
discovered in an advanced stage were the anti-tumor effect of
metformin will not be able to sufficiently inhibit tumor
growth.[40] However, this study does not exclude the opportunity
that metformin could be a valuable adjuvant therapy in other
cancer types or only in patients with resectable, early stage
pancreatic cancer. Nowadays, new oncology drugs are very
expensive and drug repurposing is an attractive strategy to offer
more effective options for patients with cancer.[41]
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